Huaiyin District Center for Disease Control and Prevention
Huaian, Jiangsu, 223399, China
NCT Number: NCT06614816
Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years: A Phase III, Randomized, Double-Blind, Active-Controlled Study
Looking for future studies?
Notify Me1 year–12 year
All sexes
Interventional
Phase 3
Huaian, Jiangsu, 223399, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
lyophilized powder, subcutaneous injection
Time frame: 42 days after completing the full course of vaccination.
The primary immunogenicity endpoint was the seroconversion rate of VZV antibodies
Time frame: 42 days after completing the full course of vaccination.
geometric mean titer (GMT) of VZV antibodies 42 days after vaccination
Time frame: 42 days after completing the full course of vaccination.
geometric mean fold increase (GMFI) of VZV antibodies 42 days after vaccination
Southeast University, China
Other
Phase III Clinical Trial of Lyophilized Live Attenuated Varicella Vaccine for Children Aged 1-12 Years
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06592456
Chickenpox Vaccines
Huaian, Jiangsu, China
View Trial DetailsNCT00226499
Chickenpox, Chickenpox Vaccines
Brno, Czechia
View Trial DetailsNCT00679796
Chickenpox, Chickenpox Vaccines
Baldham, Bavaria, Germany
View Trial Details